Literature DB >> 7530656

Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL.

T Matsuguchi1, R C Inhorn, N Carlesso, G Xu, B Druker, J D Griffin.   

Abstract

Vav is a recently described proto-oncogene expressed only in hematopoietic cells which contains an SH2 and two SH3 domains and shares homology with the Dbl GDP-GTP exchange factor and BCR. p95Vav is phosphorylated on tyrosine residues in response to stimulation of the T cell antigen receptor, cross-linking of IgE or IgM receptors and stimulation of immature hematopoietic cells by Steel factor. Monoclonal antibodies to human Vav were generated and used to examine the events which regulate tyrosine phosphorylation of p95Vav in myeloid cells. In the factor-dependent MO7e cell line, p95Vav was rapidly phosphorylated on tyrosine residues in a dose- and time-dependent manner by GM-CSF, IL-3 and Steel factor. Introduction of the BCR/ABL oncogene into this cell line resulted in factor-independent proliferation and constitutive phosphorylation of p95Vav. Tyrosine phosphorylation of p95Vav was also substantially increased by treatment of cytokine-deprived cells with the tyrosine phosphatase inhibitor sodium vanadate. Since many of the cytokines known to induce tyrosine phosphorylation of p95Vav are also known to activate JAK family tyrosine kinases, we looked for an interaction of p95Vav with JAK kinases. p95Vav co-precipitated with JAK2 in MO7e cells stimulated with GM-CSF, but not in unstimulated cells. Also, JAK2 was found to be constitutively associated with p95Vav in vivo when expressed at high levels in insect cells using baculovirus vectors. A fusion protein consisting of glutathione-S-transferase and the SH2 domain of p95Vav (GST-Vav-SH2) precipitated JAK2, suggesting that this interaction is mediated by the SH2 domain of p95Vav.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530656      PMCID: PMC398079          DOI: 10.1002/j.1460-2075.1995.tb06999.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  38 in total

1.  Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line.

Authors:  P Laneuville; N Heisterkamp; J Groffen
Journal:  Oncogene       Date:  1991-02       Impact factor: 9.867

2.  Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product.

Authors:  W G Kaelin; D C Pallas; J A DeCaprio; F J Kaye; D M Livingston
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

Review 3.  Leukemia and the disruption of normal hematopoiesis.

Authors:  C L Sawyers; C T Denny; O N Witte
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 4.  Molecular insights into the Philadelphia translocation.

Authors:  N Heisterkamp; J Groffen
Journal:  Hematol Pathol       Date:  1991

5.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

6.  Mechanism of activation of the vav protooncogene.

Authors:  J Coppola; S Bryant; T Koda; D Conway; M Barbacid
Journal:  Cell Growth Differ       Date:  1991-02

7.  BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.

Authors:  A M Pendergast; A J Muller; M H Havlik; Y Maru; O N Witte
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

8.  Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases.

Authors:  M Rozakis-Adcock; J McGlade; G Mbamalu; G Pelicci; R Daly; W Li; A Batzer; S Thomas; J Brugge; P G Pelicci; J Schlessinger; T Pawson
Journal:  Nature       Date:  1992-12-17       Impact factor: 49.962

9.  Expression of myeloid differentiation antigens on normal and malignant myeloid cells.

Authors:  J D Griffin; J Ritz; L M Nadler; S F Schlossman
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells.

Authors:  K Okuda; B Druker; Y Kanakura; M Koenigsmann; J D Griffin
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113

View more
  22 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion.

Authors:  Rubén A Bartolomé; Isabel Molina-Ortiz; Rafael Samaniego; Paloma Sánchez-Mateos; Xosé R Bustelo; Joaquin Teixidó
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

3.  Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin alpha4beta1.

Authors:  David García-Bernal; Natalia Wright; Elena Sotillo-Mallo; César Nombela-Arrieta; Jens V Stein; Xosé R Bustelo; Joaquin Teixidó
Journal:  Mol Biol Cell       Date:  2005-05-04       Impact factor: 4.138

4.  Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.

Authors:  Young Jin Cho; Bin Zhang; Vesa Kaartinen; Leena Haataja; Ivan de Curtis; John Groffen; Nora Heisterkamp
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

5.  Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42.

Authors:  Gina L Razidlo; Kevin M Burton; Mark A McNiven
Journal:  J Biol Chem       Date:  2018-05-31       Impact factor: 5.157

6.  Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins.

Authors:  Daniela Poppe; Imke Tiede; Gerhard Fritz; Christoph Becker; Brigitte Bartsch; Stefan Wirtz; Dennis Strand; Shinya Tanaka; Peter R Galle; Xosé R Bustelo; Markus F Neurath
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

7.  Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation.

Authors:  J C Mulloy; T S Migone; T M Ross; N Ton; P L Green; W J Leonard; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.

Authors:  G Bazzoni; N Carlesso; J D Griffin; M E Hemler
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

9.  Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.

Authors:  K R LaMontagne; A J Flint; B R Franza; A M Pandergast; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

10.  Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors.

Authors:  A Pandey; A V Podtelejnikov; B Blagoev; X R Bustelo; M Mann; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.